These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 30656969)

  • 21. Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
    Slaoui M; Zoure AA; Mouh FZ; Bensouda Y; El Mzibri M; Bakri Y; Amrani M
    BMC Cancer; 2018 Jul; 18(1):713. PubMed ID: 29976157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer. Single institution experience.
    Kolarevic D; Tomasevic Z; Dzodic R; Gavrilovic D; Zegarac M
    J BUON; 2012; 17(1):21-6. PubMed ID: 22517688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.
    Horváth Z; Torday L; Hitre E; Ganofszky E; Juhos E; Czeglédi F; Urbán L; Polgár C; Láng I; Eckhardt S; Kásler M
    Pathol Oncol Res; 2011 Sep; 17(3):541-50. PubMed ID: 21153723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
    Genet D; Lejeune C; Bonnier P; Aubard Y; Venat-Bouvet L; Adjadj DJ; Martin J; Labourey JL; Benyoub A; Clavère P; Lebrun-Ly V; Juin P; Piana L; Tubiana-Mathieu N
    Br J Cancer; 2007 Oct; 97(7):883-7. PubMed ID: 17876327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.
    Alexander A; Karakas C; Chen X; Carey JP; Yi M; Bondy M; Thompson P; Cheung KL; Ellis IO; Gong Y; Krishnamurthy S; Alvarez RH; Ueno NT; Hunt KK; Keyomarsi K
    Oncotarget; 2017 Feb; 8(9):14897-14911. PubMed ID: 28107181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
    Bertucci F; Finetti P; Colpaert C; Mamessier E; Parizel M; Dirix L; Viens P; Birnbaum D; van Laere S
    Oncotarget; 2015 May; 6(15):13506-19. PubMed ID: 25940795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
    Brzezinska M; Williams LJ; Thomas J; Michael Dixon J
    Breast Cancer Res Treat; 2016 Dec; 160(3):387-391. PubMed ID: 27757718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of inflammatory breast cancer after neoadjuvant chemotherapy.
    Abrous-Anane S; Savignoni A; Daveau C; Pierga JY; Gautier C; Reyal F; Dendale R; Campana F; Kirova YM; Fourquet A; Bollet MA
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1055-63. PubMed ID: 20478662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
    Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
    Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
    Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study.
    Song S; Wu HG; Lee CG; Keum KC; Kim MS; Ahn YC; Oh D; Park HJ; Lee SW; Park G; Moon SH; Cho KH; Kim YS; Won Y; Oh YT; Kim WT; Jeong JU
    BMC Cancer; 2017 Aug; 17(1):598. PubMed ID: 28854890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.
    Warren LE; Guo H; Regan MM; Nakhlis F; Yeh ED; Jacene HA; Hirshfield-Bartek J; Overmoyer BA; Bellon JR
    Ann Surg Oncol; 2015 Aug; 22(8):2483-91. PubMed ID: 25791789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.